{"filings":[{"id":286523,"accession_number":"0001437749-23-026832","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Fuse Medical voluntarily deregisters common stock, suspends SEC reporting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Form 15 to voluntarily deregister common stock and suspend Exchange Act reporting effective Sept 27, 2023.","Board cites cost savings, undervaluation, and low trading volume as reasons for deregistration.","Expects significant annual expense reduction from lower professional fees and compliance costs.","Will continue trading on OTC Pink (FZMD) with annual financial statements and operational updates via website.","Management to focus on long-term growth without short-term stock price distractions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286522,"accession_number":"0001437749-23-023797","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fuse Medical Q2 2023 net income $307,588 vs loss of $322,936 a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue rose 7% to $5.0M from $4.7M in Q2 2022.","Gross profit grew 31% to $3.5M (69% margin) from $2.6M (57% margin).","SG&A expense increased to $1.6M from $1.4M; commissions down slightly.","EBITDA swung to $401,574 from a loss of $246,834 year-over-year.","CEO cites growth from portfolio of Fuse branded/manufactured products and national distribution expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":8981667.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306438,"accession_number":"0001437749-23-018375","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fuse Medical holds 2023 Annual Meeting; all director nominees elected and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four director nominees elected with >98% votes for: Bosita, Brooks, Yellin, Reeg.","Ratification of M&K CPAS as independent auditor for FY2023: 64,474,346 for, 47,224 against, 191 abstain.","Quorum of 64,521,761 shares present out of 73,895,794 eligible shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306437,"accession_number":"0001564590-23-005823","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fuse Medical reports FY 2022 net income of $3.1M, swing from prior-year loss; revenue down 9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $18.6M (-9% YoY); gross profit margin improved to 62% from 58%.","Net income of $3.1M vs net loss of $1.59M in FY 2021, a swing of $4.69M.","Adjusted EBITDA loss narrowed to ~$1.0M from ~$2.0M (improvement of ~50%).","SG&A down 7% to $6.5M; commissions expense down 20% to $5.7M.","CEO Reeg: focus in 2023 on design, development, commercialization, and expanding direct sales force."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3984455.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343321,"accession_number":"0001564590-22-038196","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2022-11-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Fuse Medical appoints M&K PLLC as new auditor, replaces Armanino LLP","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Armanino engagement mutually ended effective Nov 1, 2022; no disagreements or reportable events.","Board approved M&K PLLC as independent registered public accounting firm for FY 2022.","New auditor selected through a competitive process; no prior consultations with M&K.","Armanino's reports for FY 2021 and 2020 were unqualified and not modified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343320,"accession_number":"0001564590-22-038045","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fuse Medical Q3 net loss shrinks 99% to $9.4k; revenue up 7% to $4.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $4.5M (+7% YoY); gross profit $3M (67% margin vs 56% in prior year).","Net loss improved to $9,376 from $697,036 loss; loss reduced ~99% YoY.","Adjusted EBITDA positive $131,241 vs loss of $630,549 in Q3 2021, a 121% improvement.","Launched Fuse PSS Pedicle Screw System with minimally invasive options in Q3.","Expects continued growth from new product launches and direct sales force expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":13759223.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378731,"accession_number":"0001564590-22-024362","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2022-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fuse Medical reports shareholder votes: all directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Renato V. Bosita, Jr., MD re-elected with 62,766,475 votes for, 295,105 against.","Mark W. Brooks re-elected with 62,768,965 votes for, 292,615 against.","Lawrence S. Yellin re-elected with 62,727,971 votes for, 333,609 against.","Christopher C. Reeg re-elected with 62,768,975 votes for, 292,605 against.","Ratification of Armanino LLP as auditor: 64,140,909 for, 17,381 against, 70 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378730,"accession_number":"0001564590-22-013944","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Fuse Medical appoints Lawrence S. Yellin as CFO, Treasurer, and board member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lawrence S. Yellin appointed CFO, Treasurer, and board member effective April 4, 2022.","Yellin's annual base salary $200,000; he is a CPA with MBA from Pace University.","John S. Gross ceased providing interim CFO services on same date.","Yellin will serve as audit committee financial expert; term until next annual meeting.","No family relationships or material interests disclosed per Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415939,"accession_number":"0001564590-21-060716","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2021-12-20T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Fuse Medical enters $5M secured revolving credit facility with CNH Finance, matures 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$5M revolving credit facility, maturity January 1, 2025; subject to borrowing base.","Interest at Prime Rate plus 1.75%; secured by substantially all personal property.","Proceeds used to repay Amegy Bank and SBA loans; remaining for working capital.","Covenants: current ratio ≥1.0, fixed charge coverage ≥1.0, loan turnover ≤60 days, minimum liquidity $175k.","Customary affirmative/negative covenants and events of default included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415938,"accession_number":"0001193125-21-347747","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2021-12-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Fuse Medical CFO and Director McLaughlin resigns; interim CFO engaged","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William E. McLaughlin resigned as CFO and Director on Nov 29, 2021, with no disagreements.","Company engaged CFO Consulting Partners, LLC for interim CFO services starting Dec 3, 2021.","Interim CFO will oversee financial operations and support while permanent CFO is sought.","McLaughlin also resigned from all positions with the Company and its subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415937,"accession_number":"0001564590-21-056340","cik":319016,"company_name":"Fuse Medical, Inc.","ticker":"FZMD","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Fuse Medical obtains waiver of EBITDA default; loan limit cut to $2.55M, term extended to Feb 2022","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Lender waived default for failing to meet $600K minimum EBITDA for trailing twelve months ended Sep 30, 2021.","Aggregate loan limit reduced to $2,550,000 from prior level.","Termination date extended to February 4, 2022; interest rate Prime + 1.00%.","President/Chairman Mark Brooks’ annual salary capped at $550,000 as part of amendment.","Company and guarantors released all claims against lender."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1995186.9999999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}